INDICATION & USAGE
IXIARO is a vaccine indicated for the prevention of disease caused by JE virus, approved for use in individuals 2 months of age and older.
Important Safety Information
Severe allergic reaction (e.g., anaphylaxis) after a previous dose of IXIARO, any other Japanese encephalitis vaccine, or any component of IXIARO, including protamine sulfate ─ a compound known to cause hypersensitivity reactions in some individuals ─ is a contraindication to administration of IXIARO. Individuals with a history of severe allergic reaction to another Japanese encephalitis vaccine may be referred to an allergist for evaluation if immunization with IXIARO might be considered.
Vaccination with IXIARO may not protect all individuals. Immunocompromised individuals may have a diminished immune response to IXIARO. Syncope can occur in association with administration of injectable vaccines, including IXIARO. Procedures should be in place to prevent injury from falling and manage syncopal reactions.
The most common (>10%) adverse reactions were: fever, irritability, diarrhea, and injection site redness in infants 2 months to <1 year of age; fever in children 1 to <12 years of age; pain and tenderness in adolescents 12 to <18 years of age; and, headache, myalgia, and injection site pain and tenderness in adults.
Healthcare practitioners are encouraged to report negative side effects of vaccines to the US Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC). Visit www.vaers.hhs.gov or call 1-800-822-7967. Healthcare practitioners are also encouraged to report inadvertent use in pregnant women to Valneva at 844-349-4276 (8443-IXIARO).
Please see full Prescribing Information.
Learn about the devastating consequences of JE through first-person accounts, as real patients and families affected by JE share their stories.
Never underestimate
the power of a bite.
Japanese encephalitis is a potentially devastating neurologic disease1
A traveler to any of 24 countries in Asia can be infected with Japanese encephalitis (JE) virus,1 which is related to mosquito-borne Zika, dengue, yellow fever, and West Nile viruses.2 In rare cases, JE viral infection can result in encephalitis.1
Learn more about protecting travelers from Japanese encephalitis.
Reduce Risk for Your Patients by Knowing the Facts
CLICK TO EXPAND
KEY FACTS ABOUT JAPANESE ENCEPHALITIS
One vaccine can help protect them
Learn about IXIARO®
JE is a devastating yet
vaccine-preventable disease.1,3
What is Ixiaro®?
Centers for Disease Control and Prevention (CDC)
Learn more about risk reduction strategies and vaccination for travelers at risk.
CDC Recommendations
Indication & Usage
IXIARO is a vaccine indicated for the prevention of disease caused by JE virus, approved for use in individuals 2 months of age and older.
Important Safety Information
Severe allergic reaction (e.g., anaphylaxis) after a previous dose of IXIARO, any other Japanese encephalitis vaccine, or any component of IXIARO, including protamine sulfate ─ a compound known to cause hypersensitivity reactions in some individuals ─ is a contraindication to administration of IXIARO. Individuals with a history of severe allergic reaction to another Japanese encephalitis vaccine may be referred to an allergist for evaluation if immunization with IXIARO might be considered.
Vaccination with IXIARO may not protect all individuals. Immunocompromised individuals may have a diminished immune response to IXIARO. Syncope can occur in association with administration of injectable vaccines, including IXIARO. Procedures should be in place to prevent injury from falling and manage syncopal reactions.
The most common (>10%) adverse reactions were: fever, irritability, diarrhea, and injection site redness in infants 2 months to <1 year of age; fever in children 1 to <12 years of age; pain and tenderness in adolescents 12 to <18 years of age; and, headache, myalgia, and injection site pain and tenderness in adults.
Healthcare practitioners are encouraged to report negative side effects of vaccines to the US Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC). Visit www.vaers.hhs.gov or call 1-800-822-7967. Healthcare practitioners are also encouraged to report inadvertent use in pregnant women to Valneva at 844-349-4276 (8443-IXIARO), or +1-301-556-4500.
Please see full Prescribing Information.
Valneva USA, Inc.
4550 Montgomery Ave.,
Suite 460
Bethesda, MD 20814
USA
Customer Service
+1-833-403-8778
Medical Information
+1 844 349 4276
(8443-IXIARO)
or +1-301-556-4500

This website is intended for US-based healthcare professionals.
US-IXI-2200027 | Copyright © 2022 Valneva USA, Inc. All Rights Reserved.